Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader–Willi syndrome
Authors' conclusion
Three years of GH-treatment in young adults with PWS with 33% of the pediatric dose, maintains total, verbal, and performance IQ. The emotional and behavioral disturbances remained stable and were similar compared to peers with other intellectual disabilities.
Study context
- Population
- Young adults with PWS treated with growth hormone (GH) during childhood; median age 19 (IQR 17–21) years; Dutch PWS Reference Center
- Participants
- 46 adults
- Exposure
- GH treatment for 3 years, before vs after
- Outcome
- Cognitive functioning (total, verbal and performance IQ by WAIS tests)
- Follow-up
- 3 years
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Total, verbal and performance IQ (estimated mean, 95% CI) · start vs after 3 years
Total IQ, start vs 3 years (P = .30)
66 (63-69) vs 67 (64-71)
Verbal IQ, start vs 3 years (P = .31)
65 (62-68) vs 66 (62-70)
Performance IQ, start vs 3 years (P = .42)
67 (63-70) vs 67 (63-72)
Observational data: associations, not effects.
Further findings
Total developmental behavior checklist-parents/caregivers (DBC-P) score (estimated mean) · start vs after 3 years
- Total DBC score, start vs 3 years (P = .94); no significant change
- 36.3 vs 36.5
- P50
Original publication
Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader–Willi syndrome. Eur J Endocrinol. Published 13 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →